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doi:10.1016/j.jmii.2012.01.004Background: Resistance to carbapenems is a significant therapeutic threat. The increasing
frequency of car bapenemase enzymes among Gram-negative bacilli makes their early detec-
tion and differentiation urgent. Carbapenemases belonging to Class A are most commonly
produced by members of family Enterobacteriaceae and are inhibited to various degrees by
clavulanic acid. The present study is aimed to determine the occurrence and phenotypic
detection of Class A carbapenemases in Escherichia coli and Klebsiella pneumoniae blood
isolates from septicemic patients.
Methods: A total of 75 isolates of K. pneumoniae and 25 E. coli were screened for resistance to
carbapenems by using meropenem and imipenem discs and meropenem E-test. Positive strains
were then subjected to a modified Hodge test combined with carbapenemase inhibition tests
to phenotypically detect and differentiate Class A serine carbapenemases from other classes of
carbapenem hydrolyzing enzymes.
Results: The screening test showing the number of isolates resistant to meropenem and imipe-
nem were 41 and 35 for K. pneumoniae and nine and four for E. coli, respectively. A total of 25
(33.3%) K. pneumoniae isolates and two (8.0%) E. coli isolates were classified as Class A carba-
penemase producers. Multidrug resistance with coexistence of extended spectrum-beta-lacta-
mases occurred in 44.4% isolates. However, all of the isolates were susceptible to colistin,
polymyxin B, and tigecycline by disc diffusion test.
Conclusion: We conclude from the present study that Class A carbapenemases appear to be the
predominant cause of resistance to carbapenems in Enterobacteriaceae at our center and,of Microbiology, Government Medical College Hospital, Chandigarh 160030, India.
hoo.com (N. Bansal).
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Carbapenems are commonly used to treat infections caused
by multidrug-resistant Enterobacteriaceae.1 During the last
decade, carbapenem resistance has emerged among clin-
ical isolates of the Enterobacteriaceae family, and this is
increasingly attributed to the production of carbapene-
mases.2 The rapid emergence and dissemination of these
enzymes poses a considerable threat to clinical patient
care and public health. These enzymes confer resistance to
virtually all b-lactam agents, including penicillins, cepha-
losporins, monobactams, and carbapenems.3 The carbape-
nemases fall into three classes according to their amino
acid sequence: (1) Ambler Class A serine carbapenemases
(serine beta-lactamases, inhibited by clavulanic acid), (2)
Class B metallo-carbapenemases (metallo-beta-lactamases
[MBLs], inhibited by metal chelators), and (3) Class D
oxacillinase-type carbapenemases (expanded-spectrum
oxacillinases).4 Among these enzymes, a new type of
Ambler Class A b-lactamase, the Klebsiella pneumoniae
carbapenemase (KPC), has been rapidly spreading among
K. pneumoniae isolates and other Enterobacteriaceae in
the northeastern regions of the United States and has
now spread to several regions of North and South America,
as well as in Israel, China, and Greece.5e11 Class A carba-
penemases (KPCs, Sme, not metalloenzyme carbapenemase
(NMC)-A, imipenem-hydrolyzing b-lactamase (IMI), and some
allelic variants of Guiana extended spectrum (GES)/inte-
gron-borne cephalosporinase (IBC)) have become more
prevalent within the Enterobacteriaceae family.12
Of the Class A carbapenemases, the KPC family has the
greatest potential for spread due to its location on plas-
mids, especially since it is most frequently found in K.
pneumoniae, an organism notorious for its ability to
accumulate and transfer resistance determinants. In
addition, the clonal spread seen in several epidemics
points to difficulties with infection control for this
organism.13
In general, carbapenem resistance may be mediated
by three major mechanisms: (1) the hyperproduction of
a b-lactamase with weak carbapenem-hydrolyzing activity
(such as AmpC-type cephalosporinase or an extended-
spectrum b-lactamase [ESBL]) combined with decreased
drug permeability through the outer membrane (i.e., outer
membrane porin loss or hyperproduction of efflux pumps),
(2) a decreased affinity of the penicillin binding proteins
that constitute target proteins for carbapenems, and (3)
carbapenem-hydrolyzing b-lactamase production.4,14,15
Early recognition of producers of carbapenemases has now
become mandatory, as recognition is crucial for controlling
the spread of carbapenemase-producing bacteria. A uniform
and standardized phenotypic tool for the detection of Class
A carbapenemases is still lacking.12 Despite these troublingtrends and the importance of this issue from both clinical
and public health perspectives, epidemiologic studies are
still lacking in this part of world. Keeping in view the high-
level drug resistance in our setting, we conducted this
study to determine the occurrence of Class A carbapene-
mases producing strains among K. pneumoniae and Escher-
ichia coli strains isolated from septicemic patients at our
center. In addition, we evaluated the susceptibility pattern
of these isolates to newer antibiotics.Materials and methods
A total of 100 consecutive, nonduplicate clinical isolates of
K. pneumoniae (n Z 75) and E. coli (n Z 25) from blood
were collected in our tertiary care hospital over a period of
6 months (July 2009eJanuary 2010). A retrospective record
of demographic characteristics, including age and sex of
the patient, and an association of the isolates with inten-
sive care units (ICU), inpatient units, and outpatient clinics
were maintained. All of the isolates were identified by
standard biochemical tests and antibiotic susceptibility by
Kirby-Bauer’s disc diffusion method.16,17
Screening for the ESBL production was done by placing
ceftazidime (30 mg), cefotaxime (30 mg), and cefepime
(30 mg) to improve detection of ESBL in AmpC producers.18,19
All of the isolates showing a zone diameter of 27 mm for
cefotaxime or 22 mm for ceftazidime or 14 mm for
cefepime were selected for ESBL production. ESBLs were
confirmed by the method described in the 2009 Clinical and
Laboratory Standards Institute (CLSI), also using positive
and negative controls.18 The results obtained were
confirmed using E-test strips (BioMe´rieux India Ltd., bio-
Me´rieux, Marcy l’Etoile, France) containing ceftazidime at
one end (Minimum inhibitory concentration (MIC) range,
0.5e32 mg/ml) and ceftazidime (MIC range, 0.064e4 mg/ml)
plus 4 mg/ml clavulanic acid at the other end. A  3 two-
fold concentration decrease in an MIC for ceftazidime
plus clavulanic acid versus MIC for ceftazidime alone was
inferred as positive for ESBL production.
Screening for carbapenemase production was done by
placing meropenem (10 mg) and imipenem (10 mg) discs.
Cut-off zone diameter breakpoints for carbapenemase
production were taken as 23 mm and 21 mm for mer-
openem and imipenem, respectively.20 All screening test
positive isolates were tested for meropenem MIC by E-test
(BioMe´rieux India Ltd.). The detection strategy/scheme
of Class A carbapenemase, including screening steps
and phenotypic confirmation, were followed (Fig. 1). We
confirmed Class A carbapenemases phenotypically by
combining a modified Hodge test (MHT) along with carba-
penemase inhibition tests to overcome false positive results
with MHT alone.20,21 MHT does not distinguish between
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Figure 1. Algorithm followed for phenotypic detection of Class A carbapenemases in Enterobacteriaceae. E/K Z E.coli/
K.pneumoniae; EDTA Z ethylene diamine tetra acetic acid; MBL Z metallo-beta-lactamase; MHA Z Mueller Hinton Agar;
MHT Z modified Hodge test; MIC Z minimum inhibitory concentration.
Table 1 Extended spectrum-beta-lactamase detection in
E. coli/K. pneumoniae strains
Test K. pneumoniae
(n Z 75)
E. coli (n Z 25)
Positive Negative Positive Negative
Screening test 64 11 19 6
Combined disc
diffusion test
51 13/64 17 2/19
E-test 51 13/64 17 2/19
106 V. Gupta et al.carbapenemase types and lacks sensitivity for MBL detec-
tion.13 We added boronic acid, a reversible inhibitor of
Class A carbapenemases and AmpC cephalosporinases, to
differentiate between types of carbapenemases. A nega-
tive result on MHT after the addition of boronic acid at
a concentration of 3000 mg/disc on meropenem was inter-
preted as positive for the presence of Class A carbapene-
mases or AmpC enzyme in the isolates tested.22 Further
differentiation of these two types of enzymes was per-
formed with the help of AmpC E-test (BioMe´rieux India Ltd.)
with cefotetan at one end and cefotetan plus cloxacillin at
the other end. Isolates giving a positive result (> three-fold
reduction in MIC of cefotetan) were treated as AmpC
hyperproducers and the rest were taken as true Class A
carbapenemaseeproducing strains (Fig. 1).
For a MHT, E. coli ATCC 25922 was used as the indicator
strain and K. pneumoniae ATCC BAA-1705 and K. pneumo-
niae ATCC BAA-1706 were used as positive and negative
control strains, respectively.21 All of the Class A carbape-
nemase positive isolates were also tested for susceptibility
to ciprofloxacin (5 mg), amikacin (30 mg), piperacillin/
tazobactam (100/10 mg), cefoperazone/sulbactam (75/
30 mg), colistin (10 mg), tigecycline (15 mg), and polymyxin B
(300 units). E. coli ATCC 25922 was used as the susceptible
control strain. Interpretation was done as per CLSI for
amikacin, ciprofloxacin and piperacillin/tazobactam while
for others manufacturer’s interpretative criteria were
used. The zone diameters interpreted as sensitive for these
drugs are as follows: cefoperazone/sulbactam (27 mm),
colistin (11 mm), tigecycline (19 mm), and polymyxin B
(12 mm). All the antibiotic discs were procured from BD
Diagnostics (BD, Gurgaon, Haryana, India) except for
cefoperazone/sulbactam (HiMedia Laboratories, Mumbai,India) and control strains were kindly provided to us by
Ranbaxy India Ltd (Daiichi Sankyo Research Centre, New
Delhi, India).
Results
A total of 100 isolates used in the study were from patients
with a mean age of 35.6 years. Of these 100 patients, 61
were men and the rest were women. Out of a total of 75 K.
pneumoniae, 51, 24, and none were from patients in ICUs,
wards, and attending outpatient clinics (OPDs), respec-
tively. A total of 25 E. coli isolates were distributed as nine
(ICUs), 11 (inpatients), and five (OPD). Of the total 100
isolates, 83% were ESBL-screening-test positive with higher
rates in K. pneumoniae (85.3%). There was a combined
double disc diffusion test and E-testeconfirmed ESBL
production in 68% (51 K. pneumoniae and 17 E. coli) of the
isolates (Table 1). A total of 15% of isolates (13 isolates of K.
pneumoniae and two of E. coli) that demonstrated
screening-test positive for ESBL did not show any zone of
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diffusion or E-test used for confirmation for ESBL produc-
tion. These isolates were treated as ESBL nonproducers but
were resistant to third generation cephalosporins alone as
well as in combination with a b-lactamase inhibitor.
Of the total 100 isolates screened for carbapenemase
production, 50% and 39% showed positive cut-off zone
breakpoints for meropenem (23 mm) and imipenem
(21 mm), respectively. All of the isolates positive with
imipenem were also positive with meropenem but the
opposite was not true. The results for carbapenemase
production are shown in Table 2.
A total of 25 (33.3%) K. pneumoniae and two (8.0%) E.
coli isolates were found to be positive for Class A carba-
penemase enzyme by our detection strategy, of which
88.9% (24/27) were from the ICU, 11.1% (3/27) from ward/
admitted patients, and none were from OPD patients. The
Class A carbapenemase positive isolates were mainly from
adults (77.8% [21/27]), and there was nearly equal sex
distribution (men, 55.6% [15/27]; women, 44.4% [12/27]).
Susceptibility of Class A carbapenemase producers to
other drugs was ciprofloxacin (11.1%; 3/27), amikacin
(14.8%; 4/27), piperacillin/tazobactam (18.5%; 5/27), and
cefoperazone/sulbactam (18.5%; 5/27). However, all of the
isolates were sensitive to colistin, polymyxin B, and tige-
cycline for which only the disc diffusion method was
employed.Discussion
With the spread of AmpC-, ESBL-, and carbapenemase-
producing strains across the world, it is necessary under-
stand the prevalence of these strains in hospitals. Detection
of resistant isolates would allow physicians to formulate
a policy of empirical therapy in high-risk units. Optimal use
of microbiology laboratories is essential to combat the
spread of multiple antibiotic-resistant pathogens. In the
lab, an intermediate- or resistant-carbapenem result
should always raise the suspicion of possible carbapene-
mase production.13
Recently, the CLSI issued recommendations21 for the
phenotypic screening of carbapenemase producers among
species of Enterobacteriaceae: MICs of ertapenem, mer-
openem, and imipenem of 2, 2 to 4, and 2 to 4 mg/ml,Table 2 Detection of class A carbapenemase in E. coli/K. pneu
Test K. pne
Positive
Screening test
Meropenem 41
Imipenem 35
Meropenem E-test (positive  4 mg/ml) 41
MHT 28/41
Modified BA-MHT 26/28
AmpC E-test (cefotetan/cefotetan-cloxacillin) 1/26 (AmpC
MBL E-test (imipenem/imipenem-EDTA) 0/2 (Class
Class A carbapenemase positive 25
EDTA Z ethylene diamine tetra acetic acid; MBL Z metallo-beta-lacrespectively (or a zone of inhibition by ertapenem or mer-
openem of 21 mm in diameter in the disk diffusion assay),
may indicate isolates with carbapenemase production, and
this phenotype should be confirmed by the Hodge method.
However, ertapenem is not advised as an indicator carba-
penem since it has lower specificity than imipenem and
meropenem and thus its use can cause the prevalence of
carbapenemases to be potentially high. Ertapenem is less
specific because isolates with AmpC/ESBL and decreased
permeability have higher MICs for ertapenem than for imi-
penem or meropenem.12,20 To overcome this problem, we
have used meropenem and imipenem in our study. Ideally,
for an isolate with a positive carbapenemase screen test,
a polymerase chain reactionebased molecular test should
be performed to confirm the presence of carbapenemase
genes. However, if genotypic confirmation is not readily
available in routine clinical microbiology laboratories,
delayed reporting of potential carbapenemase producers to
the clinicians should be avoided by performing phenotypic
confirmation tests. In our study, we have confirmed Class A
carbapenemases phenotypically by combining MHT along
with carbapenemase inhibition tests to overcome false
positive results with MHT alone.20 This kind of a strategy
can be followed to detect Class A carbapenemases pheno-
typically in Enterobacteriaceae.
Coexistence of ESBL and Class A carbapenemase
enzymes in E. coli and K. pneumoniae in septicemic isolates
is more threatening (12/27 in our study) because the
presence of carbapenemases increases both mortality and
morbidity. Mouloudi and others23 from Greece found KPC in
32.2% of K. pneumoniae isolates responsible for blood
stream infections among ICU patients, which is in accor-
dance with our study. By contrast, none of the isolates
possessing Class A carbapenemase were from patients
attending outpatient clinics. Thus, at present in India,
carbapenemase harboring isolates are largely restricted to
only hospitalized patients.
Most worrisome, treatment of infections caused by these
organisms is extremely difficult because of their multidrug
resistance, which results in high mortality rates. In our
study, a high degree of co-resistance to ciprofloxacin,
amikacin, ceftazidime, cefotaxime, cefepime, piperacillin/
tazobactam, and cefoperazone/sulbactam was observed in
Class A carbapenemase positive strains. All such strains,
however, showed complete susceptibility to colistin,moniae strains
umoniae (n Z 75) E. coli (n Z 25)
Negative Positive Negative
34 9 16
40 4 21
34 9 16
13/41 2/9 7/9
2/28 2/2 0/2
) 25/26 0/2 (AmpC) 2/2
B) 2/2 (Class D) 0 (Class B) 0 (Class D)
50 2 23
tamase; MHT Z modified Hodge test.
108 V. Gupta et al.tigecycline, and polymyxin B by disc diffusion method,
which needs further confirmation by employing MIC meth-
odology. These drugs may act as substitutes to treat these
infections either alone or in combination as supported by
various studies from New York, Brazil, and India.24e27
To conclude, microbiologic excellence is a timely detec-
tion of resistant pathogens and can help formulate effec-
tive prevention and infection control strategies and help
make better patient outcomes possible. This phenotypic
method is very helpful to detect carbapenemase produc-
tion and provides a simple algorithm for the differentiation
of Class A carbapenemases and MBL enzymes in Enter-
obacteriaceae in routine clinical microbiological laborato-
ries. In the present study, Class A carbapenemase appears
to be a predominant cause of carbapenem resistance in
Enterobacteriaceae in this part of India. To the best of our
knowledge, this constitutes the first report on the preva-
lence and detection of Class A carbapenemases from India.References
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